Exhibition booth will provide research, clinical trial results, and supplement samples to conference attendees
Defined Sleep, a pioneer in scientifically developed, supported, and validated CBD sleep supplements, is proud to announce its upcoming participation in the American Psychiatric Association (APA) 2024 Annual Meeting from May 4-8, 2024. This key event, held in New York City, gathers mental health professionals from around the world to connect and engage with exhibitors featuring new trends, innovations, and therapeutics in psychiatry.
At the conference, Defined Sleep will showcase its latest research findings at their exhibition booth on the critical link between sleep quality and mental health. The Defined Sleep research team, led by Dr. Paul Muchowski, will highlight evidence-based strategies for enhancing sleep hygiene to improve overall mental well-being.
Key Features of Defined Sleep's Participation in This Meeting:
- Evidence-based Research: Latest studies demonstrating the impact of sleep management on mental health.
- Expertise in Science: The founder of Defined Sleep will share information about practical sleep hygiene techniques for mental health professionals.
- Networking Opportunities: Discussions on how mental health practitioners can integrate these insights into their clinical practice.
"We are excited to bring our cutting-edge research to the forefront at the APA 2024 conference," says Dr. Paul Muchowski, Founder and Lead researcher at Defined Sleep. "Our commitment is to bridge the gap between sleep science and mental health care, providing actionable solutions that practitioners can apply in their work."
Defined Sleep’s involvement in the APA conference underscores its dedication to fostering deeper understanding and innovation in mental health care through improved sleep science.
For additional details about Defined Sleep’s role at the APA 2024 conference or to arrange an interview with Dr. Muchowski, please visit https://definedsleep.com/pages/contact-us.
About Defined Sleep
Defined Sleep is the first CBD sleep supplement using a rational drug design that includes eight terpenes, which act as amplifiers for CBD. After years of scientific research, Dr. Paul Muchowski, renowned neuroscientist with a Ph.D. from the University of Washington and further training with Dr. Ulrich Hartl at the Max Planck Institute for Biochemistry, developed Defined Sleep to further his mission to develop proprietary, clinically proven CBD-based products targeted at the relief of major human ailments. Defined Sleep is the only research-based CBD supplement backed by a clinical trial on the market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507298071/en/
Contacts
Alexis Quintal
grow@rosarium.work
